November 8th 2024
The companies will work to create climate-friendly pMDIs using Orbia’s low global warming potential propellant.
September 24th 2024
Excipient and delivery device selection play crucial roles in the formulation of inhaled drugs.
September 20th 2024
Vectura’s expertise in the field includes formulation and device development for dry powder inhalers and pressurized metered dose inhalers, among other products and services.
February 21st 2024
GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.
November 2nd 2023
A novel approach for safety assessments in inhalation drugs may avoid animal testing for drug products.